Peripheral arterial disease, which is caused by atherosclerotic occlusion of the arteries to
the legs, is an important manifestation of systemic atherosclerosis. The age-adjusted …

These guidelines address the diagnosis and management of atherosclerotic, aneurysmal,
and thromboembolic peripheral arterial diseases (PADs). The clinical manifestations of PAD …

This chapter about antithrombotic therapy for peripheral arterial occlusive disease is part of
the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence …

Lower extremity peripheral arterial disease (PAD) affects approximately 10% of the
American population, with 30% to 40% of these patients presenting with claudication …

This chapter is devoted to antithrombotic therapy for peripheral artery occlusive disease as
part of the American College of Chest Physicians Evidence-Based Clinical Practice …

Critical limb ischaemia (CLI) is a severe form of peripheral arterial disease (PAD). CLI often
causes disabling symptoms of pain and can lead to loss of the affected limb. It is also …

Aims Patients with peripheral arterial obstructive disease require treatment to prevent major
cardiovascular events and to relieve intermittent claudication. The walking performance of …

Background Anticoagulant treatment for intermittent claudication might improve functional
capacity and prevent acute cardiovascular complications caused by peripheral obstructive …

The pathogenesis of numerous cardiovascular, pulmonary, inflammatory, and
thromboembolic diseases can be related to arachidonic acid (AA) metabolites. One of these …

Background The literature on antiplatelet therapy for peripheral artery disease has
historically been summarized inconsistently, leading to conflict between international …